Atomwise joins Y Combinator program

Scanning electron micrograph of a human T cell.

Scanning electron micrograph of a human T cell. Image credit: NIAID via Flickr.

“Here I am just sitting in this house and I’m able to predict a cure to measles,” says Atomwise co-founder Alex Levy in a recent interview.

The University of Toronto startup is using advanced machine learning algorithms to discover new effective medicines against diseases such as ebola, malaria, and others. This information can decrease the cost and time required to develop new medicines, currently estimated at $2.9 billion and an average of 12 years. The potential of the company is signaled by its recent selection for participation in the prestigious Y Combinator accelerator program in California. Atomize has been working with partners such as SickKids Hospital, the Centre for Addiction and Mental Health (CAMH), and the India Institute of Technology in Bombay.

Atomwise was originally called Chematria, a startup that graduated out of Techno in 2012 at the University of Toronto. Read the Y Combinator announcement posted by U of T’s Impact Centre.

Co-founder Alex Levy is a U of T graduate and was formerly named Canada’s Top Entrepreneur in 2011 for his research and development of MyVoice, a mobile application that gives people with communication disorders like those caused by stroke, autism and ALS, a way to make themselves understood audibly. Read the full story on Alex Levy and his work with MyVoice on U of T News.